A Preview Of Iridium Comms’s Earnings

Iridium Comms (NASDAQ:IRDM) is set to give its latest quarterly earnings report on Thursday, 2023-04-20. Here’s what investors…

Iridium Comms (NASDAQ:IRDM) is set to give its latest quarterly earnings report on Thursday, 2023-04-20. Here’s what investors need to know before the announcement.

Analysts estimate that Iridium Comms will report an earnings per share (EPS) of $0.00.

Iridium Comms bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Here’s a look at Iridium Comms’s past performance and the resulting price change:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 0.02
EPS Actual -0.01 0.02 0.04 0.02
Price Change % 9.58% 2.57% 3.62% -2.06%

Stock Performance

Shares of Iridium Comms were trading at $58.82 as of April 18. Over the last 52-week period, shares are up 50.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Iridium Comms visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

iClick Interactive Asia Earnings Preview

iClick Interactive Asia (NASDAQ:ICLK) is set to give its latest quarterly earnings report on Thursday, 2022-08-25. Here's what investors need to know before the announcement. Analysts estimate that iClick Interactive Asia will report an earnings per share (EPS) of $-0.06.

ICLK

Read More

Celularity Announces Net Sales And Total Revenue Expectations; Expects Net Sales Of Its Biomaterial Products And Biobanking Businesses To Be In The Range Of $11.4M-$12.1M For Q4 2023 And $22.06M-$22.76M For FY23

Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year

CELU